Asset Details
Do you wish to reserve the book?
Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations
Do you wish to request the book?
Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations
2012
Overview
► A norovirus GII.4 Consensus virus-like particle was engineered for development as a vaccine candidate. ► Intramuscular immunization elicited strong antibody responses in rabbits. ► Antibodies developed against the Consensus GII.4 VLPs cross-reacted with a panel of VLPs representing different GII.4 variants. ► A bivalent formulation of GI.1 and GII.4 VLPs was shown to effectively induce heterotypic responses.
Noroviruses, a major cause of acute gastroenteritis worldwide, present antigenic diversity that must be considered for the development of an effective vaccine. In this study, we explored approaches to increase the broad reactivity of virus-like particle (VLP) norovirus vaccine candidates. The immunogenicity of a GII.4 “Consensus” VLP that was engineered from sequences of three genetically distinct naturally occurring GII.4 strains was examined for its ability to induce cross-reactive immune responses against different clusters of GII.4 noroviruses. Rabbits immunized with GII.4 Consensus VLPs developed high serum antibody titers against VLPs derived from a number of distinct wild-type GII.4 viruses, including some that had been circulating over 30 years ago. Because the sera exhibited low cross-reactivity with antigenically distinct GI norovirus strains, we investigated the serum antibody response to a bivalent vaccine formulation containing GI.1 (Norwalk virus) and GII.4 Consensus VLPs that was administered to animals under varying conditions. In these studies, the highest homologous and heterologous antibody titers to the bivalent vaccine were elicited following immunization of animals by the intramuscular route using Alhydrogel (Al(OH)3) as adjuvant. Our data indicate that the use of both genetically engineered norovirus VLPs that incorporate relevant epitopes from multiple strains and multivalent vaccine formulations increase the breadth of the immune response to diverse variants within a genotype and, thus, prove helpful in the rational design of VLP-based vaccines against human noroviruses.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adjuvants, Immunologic - administration & dosage
/ aluminum
/ Aluminum Hydroxide - administration & dosage
/ Animals
/ Antigens
/ Consensus virus like-particles
/ Epitopes
/ Female
/ Genotype
/ humans
/ Proteins
/ Rabbits
/ Studies
/ Vaccines
/ Vaccines, Synthetic - administration & dosage
/ Vaccines, Synthetic - genetics
/ Vaccines, Synthetic - immunology
/ Vaccines, Virosome - administration & dosage
/ Vaccines, Virosome - genetics
/ Vaccines, Virosome - immunology
/ Viral Vaccines - administration & dosage
/ viruses
